Introducing SAHPRA’s Online Directory for OTC Medicines

By Staff Writer

October 19, 2023

SAHPRA Online OTC Medicines Directory

The South African Health Products Regulatory Authority (SAHPRA) has announced a new online directory of over-the-counter (OTC) drugs. Optimised for mobile use, this directory includes all registered over-the-counter medicines in Schedule 0, 1, and 2. It serves as an essential guide for the general public and medical professionals.

Enhancing One’s Capability to Access Crucial Information

The team first introduced the online directory on January 6th, 2021, with a planned launch in May 2021. The directory aims to provide detailed information from the Patient Information Leaflet (PIL) for all registered over-the-counter products. These products include commercially available complementary medicines in South Africa, but only after their registration. If a PIL isn’t available yet, the directory will use the Professional Information (PI) instead. 

Together with the Self-Care Association of South Africa, SAHPRA have worked to compile this directory. The system will provide a secure login to every over-the-counter medicine manufacturer. The Responsible Pharmacist or any designated company representative can use this login. They will have the ability to input all relevant approved PILs for their OTC items. If a PIL isn’t available, they can enter the PI. The system will already have the names of these items loaded.

Streamlining Access to Essential Information

Users are able to swiftly and easily locate the information they require thanks to the extensive search feature provided by the SAHPRA OTC online directory. It will be possible to conduct searches in the SAHPRA OTC online directory by making reference to:

  • therapeutic category or pharmacological categorisation,
  • product name; or
  • active ingredient, such as paracetamol and aspirin.

The platform is not meant to be utilised for marketing-related activities. The only logo or branding that will be allowed is that of the SAHPRA, hence no other logos or brands will be allowed.

The introduction of this online database is a significant step toward achieving greater transparency, accountability, and accessibility in the field of healthcare.

Reference url

Recent Posts

Zimislecel type 1 diabetes
   

Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential

🚀 What if we could revolutionize Type 1 diabetes treatment?

Vertex Pharmaceuticals has made significant strides with its promising phase 1/2 trial results for **zimislecel**, a stem cell-derived therapy that not only restores insulin production but also drastically reduces severe hypoglycemic events. As phase 3 trials commence, this breakthrough could reshape care for T1D patients and potentially reduce long-term healthcare costs.

Curious to learn how zimislecel and other potential cell therapies may redefine diabetes management? Click to read more!

#SyenzaNews #biotechnology #HealthEconomics

biosimilar clinical approach
    

Biosimilar Clinical Approach

🚀 How is the EMA’s new biosimilar clinical approach changing the landscape of drug approvals in Europe?

With a focus on tailored clinical assessments, the EMA is streamlining the pathway for biosimilars by allowing analytical data to take precedence over large-scale comparative efficacy studies. This shift promises to enhance patient access to life-saving therapies while maintaining rigorous safety standards.

Dive deeper into the implications of this innovative regulatory approach and find out how it can impact health economics and market access.

👉 Read more in the full article!
#SyenzaNews #regulatoryaffairs #MarketAccess

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.